EWTX Q4 2023 Earnings — Edgewise Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

EWTXEdgewise Therapeutics, Inc.

$3B

Q4 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

$0

Operating Income

-$34M

Net Income

-$30M

EPS (Diluted)

$-0.47

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$27M

Free Cash Flow

-$27M

Stock-Based Comp.

$5M

Balance Sheet

Total Assets

$340M

Total Liabilities

$21M

Stockholders' Equity

$319M

Cash & Equivalents

$86M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	$0	$0	—
Operating Income	-$34M	-$22M	-53.4%
Net Income	-$30M	-$19M	-55.3%